224 related articles for article (PubMed ID: 30597500)
1. Recombinant Human Soluble Thrombomodulin in Sepsis-Induced Coagulopathy: An Updated Systematic Review and Meta-Analysis.
Yamakawa K; Murao S; Aihara M
Thromb Haemost; 2019 Jan; 119(1):56-65. PubMed ID: 30597500
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis.
Yamakawa K; Aihara M; Ogura H; Yuhara H; Hamasaki T; Shimazu T
J Thromb Haemost; 2015 Apr; 13(4):508-19. PubMed ID: 25581687
[TBL] [Abstract][Full Text] [Related]
3. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.
Yoshimura J; Yamakawa K; Ogura H; Umemura Y; Takahashi H; Morikawa M; Inoue Y; Fujimi S; Tanaka H; Hamasaki T; Shimazu T
Crit Care; 2015 Mar; 19(1):78. PubMed ID: 25883031
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study.
Hayakawa M; Yamakawa K; Saito S; Uchino S; Kudo D; Iizuka Y; Sanui M; Takimoto K; Mayumi T; Ono K;
Thromb Haemost; 2016 Jun; 115(6):1157-66. PubMed ID: 26939575
[TBL] [Abstract][Full Text] [Related]
5. Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial.
Vincent JL; Francois B; Zabolotskikh I; Daga MK; Lascarrou JB; Kirov MY; Pettilä V; Wittebole X; Meziani F; Mercier E; Lobo SM; Barie PS; Crowther M; Esmon CT; Fareed J; Gando S; Gorelick KJ; Levi M; Mira JP; Opal SM; Parrillo J; Russell JA; Saito H; Tsuruta K; Sakai T; Fineberg D;
JAMA; 2019 May; 321(20):1993-2002. PubMed ID: 31104069
[TBL] [Abstract][Full Text] [Related]
6. A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients.
Takazono T; Nakamura S; Imamura Y; Yoshioka S; Miyazaki T; Izumikawa K; Sawai T; Matsuo N; Yanagihara K; Suyama N; Kohno S
J Infect Chemother; 2014 Aug; 20(8):484-8. PubMed ID: 24855912
[TBL] [Abstract][Full Text] [Related]
7. Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy.
Levi M; Vincent JL; Tanaka K; Radford AH; Kayanoki T; Fineberg DA; Hoppensteadt D; Fareed J
Crit Care Med; 2020 Aug; 48(8):1140-1147. PubMed ID: 32697484
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study.
Tagami T; Matsui H; Horiguchi H; Fushimi K; Yasunaga H
J Thromb Haemost; 2015 Jan; 13(1):31-40. PubMed ID: 25393713
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation - A meta-analysis.
Kato H; Hagihara M; Asai N; Umemura T; Hirai J; Mori N; Yamagishi Y; Iwamoto T; Mikamo H
Thromb Res; 2023 Jun; 226():165-172. PubMed ID: 37182388
[TBL] [Abstract][Full Text] [Related]
10. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study.
Yamakawa K; Fujimi S; Mohri T; Matsuda H; Nakamori Y; Hirose T; Tasaki O; Ogura H; Kuwagata Y; Hamasaki T; Shimazu T
Crit Care; 2011; 15(3):R123. PubMed ID: 21569368
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.
Yamakawa K; Ogura H; Fujimi S; Morikawa M; Ogawa Y; Mohri T; Nakamori Y; Inoue Y; Kuwagata Y; Tanaka H; Hamasaki T; Shimazu T
Intensive Care Med; 2013 Apr; 39(4):644-52. PubMed ID: 23361628
[TBL] [Abstract][Full Text] [Related]
12. Factors Determining the Efficacy of Recombinant Human Thrombomodulin in the Treatment of Sepsis-Induced Disseminated Intravascular Coagulation.
Kotake K; Hongo T; Tahira A; Niimi N; Haisa I; Kawakami Y
Biol Pharm Bull; 2021 May; 44(5):605-610. PubMed ID: 33612566
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis.
Ogawa Y; Yamakawa K; Ogura H; Kiguchi T; Mohri T; Nakamori Y; Kuwagata Y; Shimazu T; Hamasaki T; Fujimi S
J Trauma Acute Care Surg; 2012 May; 72(5):1150-7. PubMed ID: 22673239
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation.
Yasuda N; Goto K; Ohchi Y; Abe T; Koga H; Kitano T
J Crit Care; 2016 Dec; 36():29-34. PubMed ID: 27546744
[TBL] [Abstract][Full Text] [Related]
15. Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial.
Hagiwara A; Tanaka N; Uemura T; Matsuda W; Kimura A
BMJ Open; 2016 Dec; 6(12):e012850. PubMed ID: 28039291
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of recombinant human soluble thrombomodulin for obstetric disseminated intravascular coagulation: a retrospective study.
Yoshihara M; Uno K; Tano S; Mayama M; Ukai M; Kondo S; Kokabu T; Kishigami Y; Oguchi H
Crit Care; 2015 Oct; 19():369. PubMed ID: 26481315
[TBL] [Abstract][Full Text] [Related]
17. Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential.
Ito T; Thachil J; Asakura H; Levy JH; Iba T
Crit Care; 2019 Aug; 23(1):280. PubMed ID: 31416465
[TBL] [Abstract][Full Text] [Related]
18. Web-based application for predicting the potential target phenotype for recombinant human thrombomodulin therapy in patients with sepsis: analysis of three multicentre registries.
Goto T; Kudo D; Uchimido R; Hayakawa M; Yamakawa K; Abe T; Shiraishi A; Kushimoto S
Crit Care; 2022 May; 26(1):145. PubMed ID: 35590381
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation.
Vincent JL; Ramesh MK; Ernest D; LaRosa SP; Pachl J; Aikawa N; Hoste E; Levy H; Hirman J; Levi M; Daga M; Kutsogiannis DJ; Crowther M; Bernard GR; Devriendt J; Puigserver JV; Blanzaco DU; Esmon CT; Parrillo JE; Guzzi L; Henderson SJ; Pothirat C; Mehta P; Fareed J; Talwar D; Tsuruta K; Gorelick KJ; Osawa Y; Kaul I
Crit Care Med; 2013 Sep; 41(9):2069-79. PubMed ID: 23979365
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human soluble thrombomodulin and short-term mortality of infection patients with DIC: a meta-analysis.
Zhang C; Wang H; Yang H; Tong Z
Am J Emerg Med; 2016 Sep; 34(9):1876-82. PubMed ID: 27452884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
